GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today successful first surgeries using the company’s new Equinoxe® Resurfacing Humeral Head, which expands Exactech’s Equinoxe® Platform Shoulder System.
“The Resurfacing Head broadens the Equinoxe shoulder line and gives surgeons the ability to address the continuum of care for shoulder arthroplasty – from early intervention to the most complex revisions. Having a complete shoulder system also creates contractual advantages with hospital systems around the world and should help us maintain our status as the fastest growing shoulder system,” said Darin Johnson, VP of Marketing, Extremities and Hips, at Exactech.
Exactech designed the Resurfacing Humeral Head in collaboration with surgeon consultants including Pierre-Henri Flurin, MD, Curtis Noel, MD, Felix “Buddy” Savoie, MD, Ryan Simovitch, MD, Thomas W. Wright, MD, and Joseph D. Zuckerman, MD. Together, they created low-profile instrumentation designed to facilitate seamless transitions between surgical steps; the anatomic sizing of the device is designed to prevent overstuffing of the joint and aid in restoring the patient’s own unique humeral head anatomy.
After completing the first surgery, Curtis Noel, MD, said, “This case was smooth and surgeon friendly. We all agreed that it was important to design an implant that would easily adapt to most any anatomy, including difficult deformities, and it accomplished that goal today. We designed a system of humeral heads to minimize the amount of humeral reaming and added initial biologic fixation while being ever mindful to keep it revision friendly.”
Ryan Simovitch, MD, added, “Because each patient has unique pathology and anatomy, precision is critical when resurfacing the shoulder. This is why we developed a system that allows all steps -- from bone preparation to prosthetic implantation -- to be performed over a single threaded guide-wire, thus minimizing the risk of malpositioning. This new device will transform how I treat challenging deformities and younger arthritic patients.”
Buddy Savoie, MD, offered, “I implanted the prosthesis through the rotator interval without ever violating the integrity of the subscapularis, and it was a quick, efficient procedure. The modular design and low-profile instrumentation facilitated implantation through a cuff-preserving approach, leaving the subscapularis essentially intact. Having a new surgical option to treat younger arthritic patients with a less invasive approach may lead to speedier recovery and quicker rehab for more active patients.”
The Equinoxe system’s success in meeting surgeon and patient needs has made it the fastest growing shoulder replacement system in the U.S. for several years.
Surgeons can learn more about the entire Equinoxe system including the new Resurfacing Humeral Head at Exactech’s educational exhibit, Booth #2261, during the American Academy of Orthopaedic Surgeons 2014 Annual Meeting, March 12 – 14 in New Orleans. More information about all the new Exactech innovations is available at http://www.exac.com/academy.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.